New cocktail may help kidney transplants last longer
NCT ID NCT03737136
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tested whether adding the drug bortezomib to a standard treatment (rituximab, plasma exchange, and IVIG) helps control antibody-mediated rejection in kidney transplant patients. Twenty participants received either the standard treatment alone or with bortezomib. The goal was to see if the combination improves kidney function and reduces rejection signs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SBMU
Tehran, Iran
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bortezomib (Velcade) added to rituximab, plasma exchange, and IVIG
What this could lead to
If adding bortezomib works better, it could help more kidney transplants survive longer by controlling rejection.
What could go wrong
This is a very small, early study (20 people) with no phase designation. The results may not apply to all patients, and bortezomib can cause side effects like nerve damage and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.